Skip to main content
Premium Trial:

Request an Annual Quote

Ronald Lowy, David Agus, Mari Baker, David Brailer, John Doerr, Dana Mead, Jr., Sue Siegel, Carlos Camargo, Daniel Federman, Bruce Landon, Redonda Miller, Michael Nierenberg, Jeffrey Trent, David Botstein, Isaac Kohane, Nicholas Schork, Dietrich Stephan,

Ronald Lowy has joined the board of directors of Helicos BioSciences, the company said this week. He is the former president and CEO of Fisher Biosciences, a division of Fisher Scientific (now Thermo Fisher Scientific). Prior to that, he was president of global connectivity solutions for ADC Telecommunications. He also served as president and chief operating officer at Krone.

Consumer genomics company Navigenics this week announced its board of directors and advisors.
The board of directors includes David Agus, a company cofounder; Mari Baker, Navigenics’ president and CEO; David Brailer, chairman of Health Evolution Partners; John Doerr, a partner of Kleiner Perkins Caufield and Byers; Dana Mead, Jr., also a partner of Kleiner Perkins Caufield and Byers; and Sue Siegel, a partner of Mohr Davidow Ventures.
Agus chairs the clinical advisory board. He is the research director of the Louis Warschaw Prostate Cancer Center and director of the Spielberg Family Center for Applied Proteomics at Cedars-Sinai Medical Center and a cofounder of Navigenics. Additional members of the clinical advisory board are Carlos Camargo, an emeritus clinical professor of medicine at Stanford University; Daniel Federman, a professor of medicine at Harvard Medical School; Bruce Landon, an associate professor of healthcare at Harvard Medical School and associate professor of medicine at Beth Israel Deaconess Medical Center; Redonda Miller, an associate professor of medicine at Johns Hopkins University; and Michael Nierenberg, medical director of Navigenics and emeritus clinical professor of medicine at Stanford University.
Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute in Arizona, chairs Navigenics’ scientific advisory board. The other SAB members are David Botstein, professor of genomics at Princeton University; Isaac Kohane, professor of pediatrics and health sciences as well as health sciences and technology at Harvard Medical School; Nicholas Schork, director of research at Scripps Genomic Medicine and professor of molecular and experimental medicine at the Scripps Research Institute; Dietrich Stephan, cofounder and chief science officer of Navigenics and deputy director for discovery research at TGen.
Peggy Conrad is the chair of Navigenics’ genetic counseling task force. She is a practicing genetic counselor with more than 10 years' experience in hereditary cancer genetics. Additional members of the task force are Elissa Levin, genetics counseling program director at Navigenics; and Kelly Ormond, associate professor of genetics and director of the human genetics and genetic counseling graduate training program at Stanford.
Greg Simon chairs the policy and ethics task force. He is the president of FasterCures-The Center for Accelerating Medical Solutions. Other members of that task force are Rachel Grob, associate dean of graduate studies and director of the Child Development Institute at Sarah Lawrence College; Kathi Hanna, an analyst, writer, and editor specializing in biomedical research policy and previously research director and editorial consultant to President Clinton's National Bioethics Advisory Commission; and Paul Slovic, founder and president of Decision Research.

Perlegen said last week that it has made three hires “to help the company prepare for several key landmark drug response studies”
Ellen Beasley joins the company as vice president of project management. Prior to that, she held a number of positions at Celera, including senior director of therapeutics alliances, senior director of bioinformatics, and director of gene discovery. Prior to Celera, she was a project manager at the Stanford Human Genome Center. Beasley holds a PhD from the University of Chicago and a BS from Trinity College in Hartford, Conn.
Keith Joho has become Perlegen’s chief information officer. Previously, he was senior vice president of research and product management at Ingenuity Systems. Prior to that, he was vice president of informatics and bioanalytical operations at SurroMed and director of bioinformatics at Abgenix. He has also held positions at Roche Bioscience, Sugen, and was on the faculty of the department of biochemistry and molecular biology at the LSU Medical Center in New Orleans. Joho obtained a PhD in microbiology at the Robert Wood Johnson Medical School.
Jeff Otto joins Perlegen this month as vice president of production operations. He has held roles at Genaissance Pharmaceuticals, where he was responsible for the genotyping services business, and most recently at Sequenom, where he started the services business. Otto received a PhD in biology at Marquette University and an MBA at the New York Institute of Technology.

Jim Evans, vice president of finance for Myriad Genetics, has been promoted to chief financial officer, Myriad said last week. He replaces Jay Moyes, who retired from the company to pursue race car driving. The company said it “admonishes Jay to drive safely.”

John Fazio has joined the board of directors of Sequenom, the company said last week. He is a former senior general practice partner of PricewaterhouseCoopers, bringing the number of directors to eight. He is a certified public accountant and certified management accountant. Fazio graduated from Penn State University and obtained a master's degree from Ohio State University.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.